XML 65 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
5. Commitments and Contingencies (Details)
1 Months Ended 12 Months Ended
Mar. 31, 2018
shares
Sep. 30, 2017
USD ($)
Apr. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
$ / shares
shares
May 31, 2016
USD ($)
Jan. 31, 2016
USD ($)
Jan. 31, 2016
CAD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Aug. 31, 2016
shares
Mar. 31, 2016
USD ($)
shares
Jan. 30, 2016
USD ($)
Jan. 02, 2016
Percentage of Royalty                         3.00%
Royalty Expense             $ 5,000            
Research and development               $ 171,078 $ 444,007        
Accrued Salaries, Current               187,500          
Officers' Compensation               $ 5,000          
Testosterone Replacement Therapy | Milestone One                          
Milestone Payments             5,000            
Testosterone Replacement Therapy | Milestone Two                          
Milestone Payments             25,000            
Testosterone Replacement Therapy | Milestone Three                          
Milestone Payments             50,000            
Testosterone Replacement Therapy | Milestone Four                          
Milestone Payments             100,000            
Testosterone Replacement Therapy | Milestone Five                          
Milestone Payments             300,000            
Alzheimer Disease | Milestone One                          
Milestone Payments             5,000            
Alzheimer Disease | Milestone Two                          
Milestone Payments             50,000            
Alzheimer Disease | Milestone Three                          
Milestone Payments             $ 200,000            
Series A financing                          
Percentage of Issued and Outstanding Shares Issued As Milestone Payments                     5.00%    
Common Stock Shares Issued for Milestone Payment | shares                     1,652,632    
McGill                          
Shares, Issued | shares                   300,000      
Equity Method Investment, Ownership Percentage                   5.00%      
Research Agreement                          
Amount Payable Under Agreement                     $ 130,000 $ 130,000  
Research and development   $ 55,000 $ 20,000                    
Research Agreement | Transaction One                          
Research and development           $ 65,000              
Research Agreement | Transaction Two                          
Research and development         $ 65,000                
Employment Agreements | Chief Executive Officer                          
Salaries, Wages and Officers' Compensation       $ 150,000                  
Additional Capital to be Raised as Target       $ 750,000                  
Warrants Issued | shares       250,000                  
Investment Warrants, Exercise Price | $ / shares       $ 0.40                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares 125,000     125,000                  
Employment Agreements | CFO                          
Salaries, Wages and Officers' Compensation       $ 75,000                  
Additional Capital to be Raised as Target       $ 750,000                  
Warrants Issued | shares       500,000                  
Investment Warrants, Exercise Price | $ / shares       $ 0.40                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares 250,000     250,000